EXOZYMES INC. Increase (Decrease) in Accounts Payable and Other Operating Liabilities
EXOZYMES INC. (EXOZ) reported Increase (Decrease) in Accounts Payable and Other Operating Liabilities of $38.89 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities · last filed 2026-08-13
- EXOZYMES INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2026-06-30 was $40.15K.
- EXOZYMES INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2026-03-31 was -$1.26K, a 100.85% decline year-over-year.
- EXOZYMES INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2025-12-31 was $330.98K, a 10.24% increase year-over-year.
- EXOZYMES INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2025-09-30 was -$26.28K, a 109.62% decline year-over-year.
- EXOZYMES INC. increase (decrease) in accounts payable and other operating liabilities for fiscal 2025 was $311.08K, a 40.55% increase from fiscal 2024.
- EXOZYMES INC. increase (decrease) in accounts payable and other operating liabilities for fiscal 2024 was $221.34K, a 18.89% decline from fiscal 2023.
- EXOZYMES INC. increase (decrease) in accounts payable and other operating liabilities for fiscal 2023 was $272.89K.
| Period end | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 3 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 6 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 9 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $40.15K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $38.89K 10-Q · filed 2026-08-13 | $369.87K derived: sum of 3 quarters · filed 2026-08-13 | $343.60K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$1.26K 10-Q · filed 2026-05-14 | $329.73K derived: sum of 2 quarters · filed 2026-05-14 | $303.45K derived: sum of 3 quarters · filed 2026-05-14 | $162.28K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $330.98K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $304.71K derived: sum of 2 quarters · filed 2026-03-30 | $163.54K derived: sum of 3 quarters · filed 2026-08-13 | $311.08K 10-K · filed 2026-03-30 |
| 2025-09-30 | -$26.28K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$167.45K derived: sum of 2 quarters · filed 2026-08-13 | -$19.90K 10-Q · filed 2025-11-13 | $280.35K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$141.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $6.38K 10-Q · filed 2026-08-13 | $306.62K derived: sum of 3 quarters · filed 2026-08-13 | $579.81K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $147.55K 10-Q · filed 2026-05-14 | $447.79K derived: sum of 2 quarters · filed 2026-05-14 | $720.98K derived: sum of 3 quarters · filed 2026-05-14 | $315.12K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $300.25K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $573.43K derived: sum of 2 quarters · filed 2026-03-30 | $167.57K derived: sum of 3 quarters · filed 2026-03-30 | $221.34K 10-K · filed 2026-03-30 |
| 2024-09-30 | $273.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$132.67K derived: sum of 2 quarters · filed 2025-11-13 | -$78.91K 10-Q · filed 2025-11-13 | $320.45K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$405.86K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$352.09K 10-Q · filed 2025-08-12 | $47.27K derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | $53.77K 10-Q · filed 2025-05-12 | $453.12K derived: sum of 2 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $399.36K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $272.89K 10-K · filed 2025-03-31 | ||
| 2023-09-30 | -$126.47K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |